Diabetes Mellitus News and Research RSS Feed - Diabetes Mellitus News and Research

Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Both spouses and first-degree relatives of patients with celiac disease are at increased risk of nonceliac autoimmune disease, according to a study in the July issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. This risk represents a mixture of genetic, environmental and ascertainment bias mechanisms. [More]
Neighborhood physical and social environments may affect type 2 diabetes risk

Neighborhood physical and social environments may affect type 2 diabetes risk

Neighborhood resources to support greater physical activity and, to a lesser extent, healthy diets appear to be associated with a lower incidence of type 2 diabetes, although the results vary by the method of measurement used, according to an article published online by JAMA Internal Medicine. [More]
ACT intervention may be effective in reducing risk for cardiovascular disease

ACT intervention may be effective in reducing risk for cardiovascular disease

A controlled study published in the current issue of Psychotherapy and Psychosomatic indicates the usefulness of a brief behavioral intervention targeting psychological risk factors for vascular disease. [More]
Ortho Clinical Diagnostics announces FDA approval of VITROS Chemistry Products HbA1c Reagent Kit for diagnosis of diabetes

Ortho Clinical Diagnostics announces FDA approval of VITROS Chemistry Products HbA1c Reagent Kit for diagnosis of diabetes

Ortho Clinical Diagnostics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the VITROS Chemistry Products HbA1c Reagent Kit to be used on the VITROS 5600 Integrated System, VITROS 4600 Chemistry System, and the VITROS 5,1 FS Chemistry System. The test can be used for the quantitative determination of percent glycated hemoglobin A1c (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in human whole blood. [More]
Helmholtz Zentrum München scientists identify how Epstein-Barr virus conceals in human cells

Helmholtz Zentrum München scientists identify how Epstein-Barr virus conceals in human cells

Scientists at Helmholtz Zentrum München have now discovered how Epstein-Barr virus (EBV) conceals itself in human cells. A main culprit for its bad visibility by the immune system is the viral protein LMP2A. As published in the scientific journal PLOS Pathogens, the protein helps EBV-infected cells hide from T cells. This camouflage through the LMP2A protein may play a major role in the causation of cancer by EBV. [More]
People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health as rates of nonfatal diseases and injuries - including diabetes and hearing loss - decline more slowly than death rates, according to a new analysis of 301 diseases and injuries in 188 countries. [More]
Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk. [More]
New therapeutic target discovered for idiopathic pulmonary fibrosis

New therapeutic target discovered for idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease for which as yet no causal therapy exists. It is, however, known that the lung interstitium - the connective tissue between the air sacs in the lower part of the lung - is affected. [More]
Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston. [More]
New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

Resverlogix Corp. today announced that new data on RVX-208 was presented at the ERA-EDTA Congress in London, England in a poster entitled: "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects with a History of CVD, and Chronic Kidney Disease (CKD); a Post-hoc Analysis of Patients from the ASSERT, SUSTAIN and ASSURE Clinical Trials." [More]
FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

The U.S. Food and Drug Administration (FDA) has approved Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, Eli Lilly and Company announced today. Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog. [More]
New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston. [More]
Heart rate measures could identify individuals with higher risk of diabetes

Heart rate measures could identify individuals with higher risk of diabetes

An association between resting heart rate and diabetes suggests that heart rate measures could identify individuals with a higher future risk of diabetes, according to an international team of researchers. [More]
Tandem Diabetes Care announces release of t:flex Insulin Pump

Tandem Diabetes Care announces release of t:flex Insulin Pump

Tandem Diabetes Care, Inc., a medical device company and manufacturer of the t:slim Insulin Pump, today announced that it is now taking orders for the t:flex Insulin Pump, with shipments planned to begin in June. The 480-unit t:flex Pump, cleared by the U.S. Food and Drug Administration in January 2015, is the largest capacity insulin pump currently offered in the United States. [More]
New Johns Hopkins-led research suggests risk factors for developing acute kidney injury

New Johns Hopkins-led research suggests risk factors for developing acute kidney injury

Physicians treating hospitalized patients for conditions unrelated to the kidneys should pay close attention to common blood and urine tests for kidney function in order to prevent incidental injury to the organs that help cleanse the body of toxins, new Johns Hopkins Bloomberg School of Public Health-led research suggests. [More]
Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015. [More]
Diabetic neuropathy highly prevalent among diabetic patients in Romania

Diabetic neuropathy highly prevalent among diabetic patients in Romania

A survey of 25,000 Romanians with diabetes has revealed that diabetic neuropathy (DN), a complication of diabetes, is highly prevalent in these patients, even in the absence of a diagnostic, and has an important impact on patients' quality of life. [More]
Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix Corp. today announced that it has entered into a Framework Agreement which sets forth the principal business terms for an equity investment and a license of RVX-208, for all indications, to Shenzhen Hepalink Pharmaceutical Co., Ltd. for China, Hong Kong, Taiwan and Macau (the "Territories"). [More]
Study shows NASH linked to 50% higher death rates compared with NAFLD

Study shows NASH linked to 50% higher death rates compared with NAFLD

Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD). [More]

Tandem Diabetes Care commences shipments of t:slim Insulin Pumps with enhanced software

Tandem Diabetes Care, Inc., a medical device company and manufacturer of the t:slim and t:flex Insulin Pumps, today commenced shipments of t:slim Pumps featuring enhanced software. [More]
Advertisement
Advertisement